Mirzyme Therapeutics Limited

MirZyme Therapeutics is an award-winning, clinical-stage biotech revolutionising maternal health by tackling preeclampsia and fetal growth restriction. Founded by Prof. Asif Ahmed, MirZyme integrates the regulatory-approved M-PREG® diagnostic with first-in-class, orally active therapeutics (MZe786 & MZe686), developing the first precision medicine for pregnancy complications. With regulatory accolades, strong partnerships, and a validated pipeline, MirZyme shifts care from reactive to proactive.